GSK announces China’s NMPA approved Nucala as add-on maintenance treatment

GSK (GSK) announced that China’s National Medical Products Administration, NMPA, has approved Nucala as add-on maintenance treatment of adult patients with inadequately controlled COPD characterised by raised blood eosinophils. The approval was based on data from the positive MATINEE and METREX phase III trials. Across these trials, mepolizumab showed a clinically meaningful and statistically significant reduction in the annualised rate of moderate/severe exacerbations versus placebo plus standard of care in a wide spectrum of COPD patients with an eosinophilic phenotype. The incidence of adverse events was similar between placebo and mepolizumab groups.